» Articles » PMID: 22209691

Autoantigenesis: the Evolution of Protein Modifications in Autoimmune Disease

Overview
Publisher Elsevier
Date 2012 Jan 3
PMID 22209691
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Protein targets in autoimmune disease vary in location, originating within cells as in system lupus erythematosus (SLE), or found on cell surfaces or in extracellular spaces. The term 'autoantigenesis' is first defined here as the changes that arise in self-proteins as they break self-tolerance and trigger autoimmune B and/or T cell responses. As illustrated in many studies, between 50 and 90% of the proteins in the human body acquire post-translational modification. In some cases, it may be that these modifications are necessary for the biological functions of proteins of the cells in which they reside or as extracellular mediators. Summarized herein, it is clear that some post-translational modifications can create new self-antigens by altering immunologic processing and presentation. While many protein modifications exist, we will focus on those created, amplified, or altered in the context of inflammation or other immune system responses. Finally, we will address how post-translational modifications in self-antigens may affect the analyses of B and T cell specificity, current diagnostic techniques, and/or the development of immunotherapies for autoimmune diseases.

Citing Articles

Antigen-driven T cell responses in rheumatic diseases: insights from T cell receptor repertoire studies.

Garrido-Mesa J, Brown M Nat Rev Rheumatol. 2025; 21(3):157-173.

PMID: 39920282 DOI: 10.1038/s41584-025-01218-9.


Senolytic Vaccines from the Central and Peripheral Tolerance Perspective.

Vasilieva M, Shatalova R, Matveeva K, Shindyapin V, Minskaia E, Ivanov R Vaccines (Basel). 2025; 12(12.

PMID: 39772050 PMC: 11680330. DOI: 10.3390/vaccines12121389.


Antigen presentation of post-translationally modified peptides in major histocompatibility complexes.

de Wit A, Bianchi F, van den Bogaart G Immunol Cell Biol. 2024; 103(2):161-177.

PMID: 39609891 PMC: 11792782. DOI: 10.1111/imcb.12839.


Antibody profiles in the mosaic of 'seronegative' APS syndrome.

Truglia S, Riitano G, Mancuso S, Recalchi S, Rapino L, Garufi C Clin Exp Immunol. 2024; 218(3):275-282.

PMID: 39192704 PMC: 11557137. DOI: 10.1093/cei/uxae079.


A Chemical Approach to Assess the Impact of Post-translational Modification on MHC Peptide Binding and Effector Cell Engagement.

Kelly J, Bloodworth N, Shao Q, Shabanowitz J, Hunt D, Meiler J ACS Chem Biol. 2024; 19(9):1991-2001.

PMID: 39150956 PMC: 11420952. DOI: 10.1021/acschembio.4c00312.


References
1.
Mor-Vaknin N, Kappes F, Dick A, Legendre M, Damoc C, Teitz-Tennenbaum S . DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. Arthritis Rheum. 2011; 63(2):556-67. PMC: 3117121. DOI: 10.1002/art.30138. View

2.
Moss C, Matthews S, Lamont D, Watts C . Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules. J Biol Chem. 2005; 280(18):18498-503. DOI: 10.1074/jbc.M501241200. View

3.
Rathmell J, Thompson C . The central effectors of cell death in the immune system. Annu Rev Immunol. 1999; 17:781-828. DOI: 10.1146/annurev.immunol.17.1.781. View

4.
ASAGA H, Yamada M, Senshu T . Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun. 1998; 243(3):641-6. DOI: 10.1006/bbrc.1998.8148. View

5.
Johnson B, Aswad D . Fragmentation of isoaspartyl peptides and proteins by carboxypeptidase Y: release of isoaspartyl dipeptides as a result of internal and external cleavage. Biochemistry. 1990; 29(18):4373-80. DOI: 10.1021/bi00470a017. View